Tissue adhesion preventing gel composition as well as preparation method and application thereof

The composite gel formed by cross-linking sodium alginate, gallic acid and calcium ions, combined with polyserine modification, overcomes the shortcomings of existing anti-adhesion materials in terms of mechanical strength, degradation behavior and biosafety, and achieves in-situ filling and continuous treatment effects on moist tissue wounds.

CN121177592APending Publication Date: 2025-12-23EAST CHINA UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511540848.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-10-27
Publication Date
2025-12-23

AI Technical Summary

Technical Problem

Existing anti-adhesion materials have shortcomings in terms of mechanical strength, degradation behavior, tissue adhesion and biocompatibility, making it difficult to effectively block wounds and actively regulate the healing microenvironment under dynamic physiological conditions.

Method used

A composite gel is formed by cross-linking sodium alginate, gallic acid, and calcium ions, and its biocompatibility is improved by polyserine modification, resulting in an anti-adhesion material with excellent tissue adhesion, mechanical adaptability, and active repair regulation function.

Benefits of technology

It achieves in-situ filling and physical barrier on moist tissue wounds, reduces the incidence of postoperative tissue adhesion, provides sustained therapeutic effects, and maintains stability and biocompatibility in dynamic physiological environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121177592A_ABST
    Figure CN121177592A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedical materials. The invention particularly relates to a tissue adhesion prevention gel composition which is mainly characterized by comprising sodium alginate, polyserine modified sodium alginate, gallic acid, calcium ions and a liquid phase. The invention also relates to a corresponding preparation method and application. According to the anti-tissue-adhesion gel composition as well as the preparation method and the application thereof, on the basis that composite gel is formed by sodium alginate and gallic acid, calcium ions are adopted for cross-linking reinforcement, and the biological safety of a tissue anti-adhesion material is further improved through polyserine grafting, so that the anti-tissue-adhesion gel composition can be effectively adhered to a postoperative wound surface, and the anti-tissue-adhesion effect is good. Tissue defect gaps are filled in situ, and a physical barrier is formed on a wound surface, so that the occurrence rate, range and severity of postoperative tissue adhesion are reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical materials technology, and particularly to the field of anti-tissue adhesion materials technology. Specifically, this invention provides an anti-tissue adhesion gel composition, its preparation method, and its application. Background Technology

[0002] Tissue adhesions, a common complication after surgery, mainly refer to abnormal fibrous connections formed between damaged tissue and adjacent organs or the tissue itself. These adhesion structures not only cause serious consequences such as chronic pain, intestinal obstruction, and female infertility, but also significantly increase the difficulty and risk of secondary surgeries, placing a heavy burden on global healthcare systems. Faced with this serious challenge, the development of efficient and biosafe anti-adhesion materials has become an urgent need.

[0003] Current clinical strategies for preventing adhesions primarily rely on two technical routes: physical barrier materials and pharmaceutical formulations. However, both have insurmountable drawbacks. Physical barrier materials, such as hyaluronic acid membranes, oxidized regenerated cellulose, and polylactic acid gels, while temporarily blocking wound contact through physical isolation, are generally limited by core issues such as insufficient mechanical strength, uncontrollable degradation behavior, and poor tissue adhesion. Polylactic acid materials, on the other hand, are too rigid to adhere to irregular wound surfaces and are prone to displacement and detachment during dynamic physiological activities. Pharmaceutical formulations, such as heparin and corticosteroids, which are anti-inflammatory and anticoagulant agents, can inhibit fibrin deposition, but systemic administration can easily lead to systemic side effects such as bleeding tendency and immunosuppression, while local administration faces problems such as drug burst release and short duration of action. More importantly, existing materials generally lack the ability to actively promote wound healing; they can only passively block adhesions and cannot regulate the repair microenvironment at the molecular level.

[0004] In recent years, hydrogels based on natural polymers (such as sodium alginate and chitosan) have attracted widespread attention due to their good biocompatibility and biodegradability. However, their single-component systems have inherent limitations due to insufficient functionality. While simple calcium alginate gel can form a physical barrier, it has poor mechanical stability and weak adhesion to moist tissues, making it prone to structural collapse under dynamic physiological conditions. Chitosan-based materials, on the other hand, may trigger local inflammatory reactions due to their acidic solubility. To improve performance, researchers have attempted to introduce chemical cross-linking agents (such as glutaraldehyde) or synthesize polymers, but this often comes at the cost of biosafety—these additives may produce cytotoxicity or interfere with the normal healing process. In addition, conventional anti-adhesion materials often employ pre-formed membrane structures, which are difficult to fully fill deep or irregular tissue defects, resulting in incomplete barrier coverage and the formation of anti-adhesion "dead zones."

[0005] To address the aforementioned technical bottlenecks, an ideal anti-adhesion material must simultaneously meet multiple stringent requirements: it must adhere tightly to moist tissue wounds for precise in-situ filling, while also possessing controllable degradation characteristics that match the tissue repair cycle; it must maintain sufficient mechanical strength to resist physiological stress, while avoiding triggering foreign body reactions or fibrotic responses; it must not only establish effective physical isolation but also actively regulate the healing microenvironment through bioactive components. Unfortunately, current technologies have not yet provided a comprehensive solution to simultaneously resolve these contradictions. Therefore, developing a novel composite gel that combines excellent tissue adhesion, mechanical adaptability, biocompatibility, and active repair regulation functions has become a key path to overcome the current limitations of anti-adhesion technology, which is precisely the core objective of this invention. Summary of the Invention

[0006] The main objective of this invention is to address the above-mentioned problems by providing an anti-tissue adhesion gel composition, its preparation method, and its application.

[0007] To achieve the above objectives, a first aspect of the present invention provides an anti-tissue adhesion gel composition, characterized in that the composition comprises sodium alginate, gallic acid, calcium ions and a liquid phase, wherein the sodium alginate comprises unmodified sodium alginate and polyserine-modified sodium alginate.

[0008] Preferably, the total mass concentration of sodium alginate is 0.5% to 5%, the polyserine-modified sodium alginate accounts for 3% to 30% of the total sodium alginate, the mass fraction of gallic acid solution is 3% to 6%, and the mass concentration of calcium ions is 0.5% to 4%.

[0009] Preferably, the sodium alginate has an average molecular weight of 50 kDa-200 kDa and a G unit content of 20%-60%.

[0010] Preferably, the composition includes a gel precursor, the gel precursor including a first component, the first component being a mixture of unmodified sodium alginate and polyserine-modified sodium alginate, wherein the volume mixing ratio of unmodified sodium alginate and polyserine-modified sodium alginate is 3:7 to 7:3.

[0011] Preferably, the gel precursor includes a second component, which is a gallic acid solution.

[0012] Preferably, the liquid phase includes one or more of deionized water, physiological saline for injection, and PBS buffer solution.

[0013] Preferably, the calcium ions are provided by one or more of CaCl2, CaCO3, or CaSO4.

[0014] A second aspect of the present invention provides a method for preparing the aforementioned anti-tissue adhesion gel composition, characterized in that it includes the following steps: S1. Prepare a first solution by mixing sodium alginate and gallic acid together; S2. Prepare a second solution by combining gallic acid and calcium ions; S3. Mix the first solution and the second solution at a volume ratio of 4 to 6:1 to form a transparent gel system. S4. Ultrasonication under an ice bath forms the final white gel.

[0015] A third aspect of the invention provides the use of the aforementioned anti-tissue adhesion gel composition in products for the prevention and treatment of tissue adhesions.

[0016] Preferably, the tissue adhesions include uterine adhesions, abdominal adhesions, and intestinal adhesions.

[0017] The anti-tissue adhesion gel composition, its preparation method, and its application of the present invention are based on a composite gel formed by sodium alginate and gallic acid, cross-linked and reinforced with calcium ions, and further improved in terms of biocompatibility by polyserine grafting. This tissue anti-adhesion material can effectively adhere to the postoperative wound, fill the gaps in tissue defects in situ, and form a physical barrier on the wound, thereby reducing the incidence, extent, and severity of postoperative tissue adhesion. Attached Figure Description

[0018] Figure 1 This is a diagram showing the physical state of the anti-tissue adhesion gel composition of the present invention at different configuration stages.

[0019] Figure 2 The graph shows the adhesion performance of the anti-tissue adhesion gel composition of the present invention.

[0020] Figure 3 This image shows the tissue adhesion results of the tissue anti-adhesion gel material (AP@E2) of the present invention and the commercially available Gong An Kang gel (GAK@E2) after 48 hours. Detailed Implementation

[0021] To provide a clearer understanding of the technical content of this invention, the following embodiments are provided in detail. However, it is important to note that these descriptions are merely for further illustrating the features and advantages of this invention, and not for limiting the scope of the claims.

[0022] Unless otherwise specified, the reagents and methods involved in the examples are all commonly used in the art.

[0023] Example 1 Preparation of polyserine-modified sodium alginate Polyserine PSe (Mn = 3700, PDI = 1.12) was synthesized using existing methods. For the synthesis of polyserine-modified sodium alginate, sodium alginate (80 kDa-100 kDa, 670 mg) was dissolved in 60 mL of a mixed solvent (53 mL deionized water and 7 mL acetonitrile). Five equivalents of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT, 1.36 g) and five equivalents of N-methylmorpholine (NMM, 853 μL) were added, and the mixture was stirred at room temperature for 30 minutes. Subsequently, 0.1 equivalents of PSe (280 mg) dissolved in 10 mL of deionized water were added to the mixture. The reaction was stirred at 60°C for 24 hours. After removing acetonitrile under reduced pressure, the mixture was successively reacted with 5 g of PSe (Mn = 3700, PDI = 1.12)... The sodium chloride solution and deionized water were dialyzed through a 10,000 MWCO membrane for three days. Finally, polyserine-modified sodium alginate (670 mg, yield 67%) was obtained by freeze-drying.

[0024] Example 2 Preparation of the anti-tissue adhesion gel material of the present invention Weigh 240 mg of gallic acid and dissolve it in 6 mL of physiological saline at 60°C to prepare a 40 mg / mL gallic acid solution; Weigh out 168 mg of polyserine-modified sodium alginate and 72 mg of unmodified pure sodium alginate, and dissolve them in 5.76 mL of the above 40 mg / mL gallic acid solution at 70°C until completely homogeneous, to obtain a sodium alginate solution with a mass concentration of approximately 4 wt% for later use. Weigh 80 mg of gallic acid and dissolve it in 2 mL of 2 wt% CaCl2 solution to obtain gallic acid-calcium chloride solution; While still hot, the sodium alginate solution and gallic acid-calcium chloride solution were rapidly mixed at a volume ratio of 5:1 with rapid stirring to form a homogeneous gel. The gel was then sonicated in an ice bath for 30 minutes to accelerate the gelation of gallic acid and form the final white composite gel.

[0025] Comparative Example 1 Weigh 168 mg of polyserine-modified sodium alginate and 72 mg of sodium alginate, dissolve them in 5.76 mL of physiological saline solution at 70 °C until completely homogeneous, and obtain a sodium alginate solution with a mass concentration of 4 wt% for later use. Prepare 2 mL of 2 wt% CaCl2 solution to dissolve and obtain calcium chloride solution; While still hot, the sodium alginate solution and calcium chloride solution were rapidly mixed at a volume ratio of 5:1 with rapid stirring to form a homogeneous gel. The mixture was then sonicated in an ice bath for 30 minutes to form the final white composite gel.

[0026] Comparative Example 2 Weigh 240 mg of gallic acid and dissolve it in 6 mL of physiological saline at 60°C to prepare a 40 mg / mL gallic acid solution; Weigh out 240 mg of unmodified sodium alginate and dissolve it in 5.76 mL of the above 40 mg / mL gallic acid solution at 70 °C until a completely homogeneous 4 wt% sodium alginate solution is obtained for later use. Weigh out 80 mg of gallic acid and dissolve it in 2 mL of 0.5 wt%, 0.25 wt%, 0.15 wt%, and 2 wt% CaCl2 solutions respectively to obtain gallic acid-calcium chloride solutions; While still hot, the sodium alginate solution and gallic acid-calcium chloride solution were rapidly mixed at a volume ratio of 5:1 with rapid stirring to form a homogeneous gel. The gel was then sonicated in an ice bath for 30 minutes to accelerate the gelation of gallic acid and form the final white composite gel.

[0027] Example 3 Injectability testing like Figure 1 As shown, the gel prepared in Example 2 has good injectability and can be easily injected into the desired location using a 24G needle.

[0028] The gel in Comparative Example 1 lacks injectable properties and cannot achieve tissue adhesion and retention. It is speculated that this may be because gallic acid polymerizes in the system and plays a key role in the interpenetrating network structure with alginate in the gel.

[0029] In Comparative Example 2, when 2 wt% calcium chloride was used, the product was tightly cross-linked into a blocky hydrogel and lost its injectability. When other concentrations of calcium chloride were used, it was injectable.

[0030] Example 4 Adhesion performance test of the anti-tissue adhesion gel material of the present invention 20 μL of the anti-adhesion material prepared in Example 2 was coated onto a clean glass plate and the endometrial tissue of 6-8 week old ICR female mice. After tilting at 60° for 12 h, the gel material adhered tightly to the glass plate and the tissue without slipping.

[0031] The gel material did not detach after being applied to the endometrium and bent and twisted 10 times, demonstrating its excellent static adhesion ability in vitro.

[0032] Further evaluation of its adhesion properties under external disturbances. Under continuous water flow of 600 μL / min, the gel material prepared in Example 2 could adhere to rat uterine endothelial tissue for more than 20 min.

[0033] Finally, a small amount of the gel material was immersed in physiological saline to study its in vitro degradation performance. The specific steps were as follows: 150 μL of the hydrogel from Example 2 was placed in a 2 ml tube, and 10 times the volume of physiological saline was added. The mixture was left to stand at room temperature for 24 hours, and the swelling and degradation of the hydrogel were observed every 12 hours.

[0034] The results are as follows Figure 2 As shown, the gel material prepared in Example 2 can effectively resist the swelling of tissue fluid and will not dissolve or disintegrate for more than 24 hours.

[0035] Compared with the three materials in Comparative Example 2 (corresponding to 0.5 wt%, 0.25 wt%, and 0.15 wt% CaCl2 solutions), the rheological properties of the gel material with added polyserine were significantly improved, with storage modulus G' and loss modulus G'' increasing by 60% and 80%, respectively. The gel appeared to be significantly more viscous. It is speculated that the large number of hydrogen bonds in polyserine makes the interaction between molecular chains in the hydrogel network stronger overall. Therefore, polyserine plays a key role in improving the overall adhesion properties of the gel.

[0036] Example 5 Retention test of the anti-tissue adhesion gel material of the present invention in the uterine cavity 10 mg of phosphoric acid choline, 2 mg of cholesterol, and 0.466 mg of DiR fluorescent dye were weighed and dissolved in chloroform solution, and 1 mg of 17β-estradiol (E2) was weighed and dissolved in methanol solution. The solutions were mixed in a flask protected from light, and sonication could be used to accelerate dissolution. The organic solvent was removed by rotary evaporation at 40°C to form a thin film, and residual solvent was removed by vacuum pumping for 3 hours. Pure water was added to hydrate the liposome film on the flask wall using ultrasonication. The film was sheared at 10,000 rpm for 3 minutes and stirred at room temperature for 30 minutes for hydration. After hydration, the film was intermittently sonicated for 15 minutes. The final DiR-labeled estradiol liposomes were obtained by further homogenization using an extruder, with an average particle size of 130.5 nm and a PDI of 0.293. The liposomes were further concentrated to 2.5 mg / mL by ultrafiltration using a 100 kDa ultrafiltration tube.

[0037] Take 900 μL of the gel material from Example 2 and add 100 μL of DIR-labeled fluorescent liposome solution to it and mix well. This mixture is labeled as AP@E2.

[0038] Take 900 μL of commercial Gong An Kang gel and add 100 μL of DiR-labeled fluorescent liposome solution to it and mix well. This mixture is labeled as GAK@E2.

[0039] The final concentration of estradiol was 0.25 mg / mL.

[0040] SD rats were anesthetized for eight weeks. A small incision was made on the ventral side to expose the uterus. 150 μL of AP@E2 or GAK@E2 was injected into the left uterine cavity using a 0.7 mm needle. The abdominal cavity was closed and the skin was sutured. The uterus was dissected for in vitro imaging 48 h later.

[0041] The results are as follows Figure 3 As shown, the fluorescence of the anti-adhesion gel material of the present invention can be retained for more than 48 hours, which can effectively remain in the application area and exert a continuous therapeutic effect; while the commercial Gong An Kang gel group was completely dissipated after 48 hours. The tissue retention performance of the anti-adhesion gel of the present invention is significantly better than that of Gong An Kang gel.

[0042] Example 6 The therapeutic application of the tissue anti-adhesion gel material of this invention in intrauterine adhesions Female SD rats aged 6-8 weeks were selected. After anesthesia, skin preparation and disinfection, a longitudinal incision of about 1 cm was made on the left side of the waist. After exposing the uterus, a transverse incision was made in the upper 1 / 3 of the uterus. The uterus was curetted with a key to create a model. The uterus was sutured, the abdomen was closed and disinfected. The same method was used to make the right side of the uterus.

[0043] After modeling, the model group was not treated in any way. After 14 days of normal feeding, the uterus was dissected, sectioned, stained, and the changes in endometrial thickness and gland number were calculated.

[0044] The treatment group needed to inject 500 μL of Example 2 hydrogel into the uterine cavity after modeling. After 14 days of feeding, the uterus was dissected, sectioned, stained, and the changes in endometrial thickness and gland number were calculated.

[0045] The results showed that the model group exhibited significant pathological changes, including glandular dilation, disordered arrangement, interstitial edema, and cavity deformation. In rats treated with hydrogel, the cavity portion recovered, the endometrium thickened by over 100%, and adhesions caused by postoperative intrauterine injury were significantly reduced.

[0046] In this specification, the invention has been described with reference to specific embodiments thereof. However, it will be apparent that various modifications and variations can be made without departing from the spirit and scope of the invention. Therefore, this specification should be considered illustrative rather than restrictive.

Claims

1. A gel composition for preventing tissue adhesion, characterized in that, The composition comprises sodium alginate, gallic acid, calcium ions, and a liquid phase, wherein the sodium alginate comprises unmodified sodium alginate and polyserine-modified sodium alginate.

2. The anti-tissue adhesion gel composition according to claim 1, characterized in that, The sodium alginate has a mass concentration of 0.5-5%, the polyserine-modified sodium alginate accounts for 3%-30% of the total sodium alginate, the gallic acid solution has a mass fraction of 3%-6%, and the calcium ion mass concentration is 0.5%-4%.

3. The anti-tissue adhesion material composition according to claim 1, characterized in that, The sodium alginate has an average molecular weight of 50 kDa-200 kDa and a G unit content of 20%-60%.

4. The anti-tissue adhesion gel composition according to claim 1, characterized in that, The composition includes a gel precursor, which includes a first component, wherein the first component is a mixture of unmodified sodium alginate and polyserine-modified sodium alginate, and the volume mixing ratio of unmodified sodium alginate and polyserine-modified sodium alginate is 3:7 to 7:

3.

5. The anti-tissue adhesion gel composition according to claim 4, characterized in that, The gel precursor includes a second component, which is a gallic acid solution.

6. The anti-tissue adhesion gel composition according to claim 1, characterized in that, The liquid phase includes one or more of deionized water, physiological saline for injection, and PBS buffer solution.

7. The anti-tissue adhesion gel composition according to claim 1, characterized in that, The calcium ions are provided by one or more of CaCl2, CaCO3 or CaSO4, and the mass concentration of the calcium ions is between 0.5% and 4%.

8. A method for preparing the anti-tissue adhesion gel composition according to claim 1, characterized in that, Includes the following steps: S1. Prepare a first solution by mixing sodium alginate and gallic acid together; S2. Prepare a second solution by combining gallic acid and calcium ions; S3. Mix the first solution and the second solution at a volume ratio of 4 to 6:1 to form a transparent gel system. S4. Ultrasonication under an ice bath forms the final white gel.

9. The use of the anti-tissue adhesion gel composition of claim 1 in products for the prevention and treatment of tissue adhesions.

10. The application according to claim 9, characterized in that, The tissue adhesions mentioned include uterine adhesions, abdominal adhesions, and intestinal adhesions.